shutterstock_1089215192_jhvephoto

jhvephoto / Shutterstock.com

15 April 2019Americas

Fresenius files IPR against Amgen

Fresenius Kabi has submitted a petition for inter partes review (IPR) of US patent number 9,856,287, a patent owned by Amgen.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Amgen wins biosimilars case against Apotex at Federal Circuit

6 July 2016 The US Court of Appeals for the Federal Circuit ruled yesterday in the Amgen v Apotex case that bisoimilars companies must always notify brand name rivals 180 days before launching their products.

Sanofi victorious at Fed Circ in prostate cancer drug dispute

15 August 2019 Sanofi secured a win at the US Court of Appeals for the Federal Circuit yesterday, August 14, after the appeals court concluded a lower court lacked authority to invalidate claims of a patent covering a prostate cancer drug.

Fresenius in patent dispute over hypocalcemia treatment

7 December 2021 Fresenius Kabi is facing a lawsuit by two Pharmasphere subsidiaries over claims that it infringed a patent covering a treatment for hypocalcemia, a condition where the blood sugar level is lower than normal.

More on this story

Amgen wins biosimilars case against Apotex at Federal Circuit

6 July 2016 The US Court of Appeals for the Federal Circuit ruled yesterday in the Amgen v Apotex case that bisoimilars companies must always notify brand name rivals 180 days before launching their products.

Sanofi victorious at Fed Circ in prostate cancer drug dispute

15 August 2019 Sanofi secured a win at the US Court of Appeals for the Federal Circuit yesterday, August 14, after the appeals court concluded a lower court lacked authority to invalidate claims of a patent covering a prostate cancer drug.

Fresenius in patent dispute over hypocalcemia treatment

7 December 2021 Fresenius Kabi is facing a lawsuit by two Pharmasphere subsidiaries over claims that it infringed a patent covering a treatment for hypocalcemia, a condition where the blood sugar level is lower than normal.

More on this story

Amgen wins biosimilars case against Apotex at Federal Circuit

6 July 2016 The US Court of Appeals for the Federal Circuit ruled yesterday in the Amgen v Apotex case that bisoimilars companies must always notify brand name rivals 180 days before launching their products.

Sanofi victorious at Fed Circ in prostate cancer drug dispute

15 August 2019 Sanofi secured a win at the US Court of Appeals for the Federal Circuit yesterday, August 14, after the appeals court concluded a lower court lacked authority to invalidate claims of a patent covering a prostate cancer drug.

Fresenius in patent dispute over hypocalcemia treatment

7 December 2021 Fresenius Kabi is facing a lawsuit by two Pharmasphere subsidiaries over claims that it infringed a patent covering a treatment for hypocalcemia, a condition where the blood sugar level is lower than normal.

More features

President Trump 2.0: Five major areas to watch

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?

Sanofi subsidiary fends off $450m trade secrets case

Regulatory expert joins White & Case

Teva faces $500m fine for antitrust breaches over MS drug